CLINICAL_TRIALS
trial_result
· 2017-02-17
Clinical Trial Update: Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour [Phase 3]
Summary
Phase 3 trial of lanreotide Autogel 120 mg in non-functioning enteropancreatic neuroendocrine tumors completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Non Functioning Entero-pancreatic Endocrine Tumour | Phase 3 | Status: COMPLETED | Results posted: 2017-02-17